1 |
1. tesofensine (ns 2330) |
Tesofensine |
- |
- |
- |
006 1件: 6 💬 |
2 |
Act-293987 (ns-304) |
- |
- |
- |
- |
086 1件: 86 💬 |
3 |
Active topical ns2 1% dermatologic cream |
- |
- |
- |
- |
160 1件: 160 💬 |
4 |
Bardoxolone methyl, cddo-me, cddo-methyl ester, nsc 713200, chemical name: oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester |
Bardoxolone |
2件: D09584 D09584, D09585 D09585 💬 |
- |
- |
086 1件: 86 💬 |
5 |
Corticosteroid or nsaid |
- |
- |
- |
- |
046 1件: 46 💬 |
6 |
Ips-nsc cells |
- |
- |
- |
- |
006 1件: 6 💬 |
7 |
Non-steroidal anti-inflammatory drug (nsaid) |
- |
- |
- |
- |
046 1件: 46 💬 |
8 |
Non-steroidal anti-inflammatory drugs (nsaids) |
- |
- |
- |
- |
107 1件: 107 💬 |
9 |
Ns |
- |
- |
- |
- |
002 1件: 2 💬 |
10 |
Ns 2330 |
- |
- |
- |
- |
006 1件: 6 💬 |
11 |
Ns-065/ncnp-01 |
- |
- |
- |
- |
113 1件: 113 💬 |
12 |
Ns-089/ncnp-02 |
- |
- |
- |
- |
113 1件: 113 💬 |
13 |
Ns-304 |
- |
- |
- |
- |
070 3件: 70, 86, 88 💬 |
14 |
Ns-304 placebo |
- |
- |
- |
- |
070 2件: 70, 88 💬 |
15 |
Ns2330 |
- |
- |
- |
- |
006 1件: 6 💬 |
16 |
Nsaids |
- |
- |
- |
- |
046 4件: 46, 70, 107, 271 💬 |
17 |
Nsaids (permitted,not necessary) |
- |
- |
- |
- |
046 1件: 46 💬 |
18 |
Nsaids and sulfasalazine |
Sulfasalazine |
1件: D00448 D00448 💬 |
- |
- |
271 1件: 271 💬 |
19 |
Nsnsaids |
- |
- |
- |
- |
271 1件: 271 💬 |
20 |
Nsp001 |
- |
- |
- |
- |
096 1件: 96 💬 |
21 |
Other non steroidal anti-inflammatory drugs (nsaids) except etodolac |
Etodolac |
1件: D00315 D00315 💬 |
PTGS2 1件: PTGS2 💬 |
Alzheimer disease 22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 1件: 46 💬 |
22 |
Other non-selective nsaids |
- |
- |
- |
- |
271 1件: 271 💬 |
23 |
Other: ns |
- |
- |
- |
- |
096 1件: 96 💬 |
24 |
Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses |
- |
- |
- |
- |
046 1件: 46 💬 |
25 |
Plantain nsp |
- |
- |
- |
- |
096 1件: 96 💬 |
26 |
Recombinant human heparan nsulfatase (rhhns) |
- |
- |
- |
- |
019 1件: 19 💬 |
27 |
Satralizumab (120 mg/pfs with nsd) |
Satralizumab |
1件: D11079 D11079 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 1件: 13 💬 |
28 |
Selexipag, act-293987 (ns-304) |
Selexipag |
1件: D09994 D09994 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |